Modern pharmaceuticals and biotechnology
When Greg Winter was a young scientist carrying out laboratory work in the 1970s, he saw the potential of using antibodies to tackle infection but had no idea of the extent to which his research would eventually be commercialised, writes Andrew Jack.
His efforts to “humanise” monoclonal antibodies (MABs) derived from mice, to tackle disease without excessive side-effects, paved the way for a modern category of medicines that has helped build the modern biotechnology industry and resuscitate large pharmaceutical companies.
您已閱讀23%（566字），剩餘77%（1860字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。
